Assessment of potential adverse events following the 2022-2023 seasonal influenza vaccines among U.S. adults aged 65 years and older

CONCLUSIONS: Rates of encephalitis/encephalomyelitis, GBS, or transverse myelitis were not elevated following 2022-2023 seasonal influenza vaccinations among U.S. adults ≥ 65 years. There was an increased rate of anaphylaxis following influenza vaccination that may have been influenced by concomitant vaccination.PMID:38704258 | DOI:10.1016/j.vaccine.2024.04.051

Source: Vaccine - May 4, 2024 Category: Allergy & Immunology Authors: Xiangyu Chianti Shi Joann F Gruber Michelle Ondari Patricia C Lloyd Pablo Freyria Duenas Tainya C Clarke Gita Nadimpalli Sylvia Cho Laurie Feinberg Mao Hu Yoganand Chillarige Jeffrey A Kelman Richard A Forshee Steven A Anderson Azadeh Shoaibi Source Type: research